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Looking for Embryonic and Fetal Stem Cells 
Repo rting in this iss ue, J ackie Bickenbach, w ho is now at the 
University of Iowa, and Karen Holbrook of the University of 
Washington School of Medi ci ne, Seattle, Washington, provide 
evidence of a subpopulation of fetal and embryoni c epiderm al 
cells that might be stem cells. 
"S tem cells," says Bickenbach, "a re immortal. " Resea rchers 
postulate that diseases th at are slow to develop must involve stem 
cell s. For example, many cancers occur after two steps- initiation 
an d promotion . Initiation occurs years before the ca ncer, whereas 
promotion occurs soon before it . So if a cell were not around for 
years, it could not be initiated . It also has been suggested that 
stem cells may be targets in diseases, such as psoriasis and som e 
of the ichth yoses, tha t involve hyperproliferation. Other in ves-
tiga tors have found a subpopulation of cells that may be stem 
cells in rodent epidermis, but it is not known whether there are 
stem cells in the human embryoni c and fetal epidermis. 
Bickenbach and Holbrook g rew epiderm al cells from human 
embryos and fetuses in organ culture and looked fo r subpopu-
lations that are slow to grow, as evidenced by their retention of 
a radioactive label of DNA . As cells divide, they make new DNA 
and so any radioactive label of their o rig inal DNA will become 
increasingly diluted by the newly fo rmed DNA . They found that 
a small percentage of th e cells-4% of th e embryoni c cells and 
2% of th e fetal cells-are slow to divide, indica ting that they may 
be stem cells. 
Understanding Why Tumors Grow 
Why do som e cells grow and become cancerous after exposure 
to a ca rcinogen w hereas others do no t? The answer may be that 
the cell s that beco me cancerous were already part-way along the 
path to a tumo r, needin g onl y exposure to a ca rcinogen to push 
them the rest of the way. In this issue, Henry Hennings, Delo res 
Michael, Ulrike Lichti, and Stuart Yuspa of the N ationa l Cancer 
Institute describe studies des igned to revea l differences between 
cells that beco m e ca ncerous and those that do no t. 
Hennings bega n this work nea rl y a decade ago when he was 
growing epidermal cells in culture with stand ard media . After 
about a week to 10 days, the cells would terminally differentiate 
and die. " More o r less by accident, we found th at if we lower 
the level of ca lcium in the medium, the cell s wi ll continue to 
grow," Hennin gs says. Hennin gs and his colleagues also found 
th at if they g rew epidermal cells in a low-ca lcium medium for 
1-2 weeks and then switched the cells to the sta ndard, hi gh cal-
cium m edium , th e cells differentiate and die. M oreover, the cells 
have surface m arkers for basa l cell s when they grow in low ca l-
cium and m arkers for differentiation w hen they gro w in high 
ca lcium. 
It occurred to H ennin gs that he might be able to use this calcium 
sys tem to select for cells th at are initiated by a ca rcinogen. To 
prod uce skin tum ors in mice, researchers first initiate the tum ors 
by treating the skin with a carcinogen and then promote the tumor 
g rowth by trea tin g with a tum o r promoter, such as a phorbol 
ester , which is not itself a carcinogen . N either the initiation no r 
the promotion alone results in a tumor. Ini tiated cells seem to 
corres pond to preneoplastic cells. 
Hennings and his colleagues began a series of experim ents in 
which they first trea ted epiderm al cells with a ca rcinogen, then 
grew th e cells in low calcium medium , and finally switched to 
hi gh calcium medium . The normal cell s died but some mutant 
cells did not . With this strategy, the in ves tigato rs isolated three 
cell lines that correspond to permanentl y initiated cells. 
Now, the question is: Ho w do thesc perm anentl y initiated cell 
lines respond to tumor promoters or to high calcium? The result , 
reported in this issue, is th at the permanentl y initi ated cell lines 
do no t differentiate in res ponse to hi gh ca lcium medium , and two 
out of three of these cclilines were stimulated to grow by phorbol 
es ter. 
Hennings concludes that tumor promoters select fo r th e growth 
of initiated cells. In normal mouse skin , he says, there are a small 
number of initiated cells that are kept under control by the un-
initi ated cells surroundin g th em. When the skin cells are exposed 
to a tumor promoter such as phorbol ester, the normal cells 
terminall y differentiate and the initiated cells continue to prolif-
erate. " When yo u trea t w ith phorbol ester once o r twice a week, 
you get rid of normal epidermal cells and leave a space for clones 
of initiated cells to grow," Hennings concludes. 
Coal Tars and Human Cancer 
Researchers at the Veterans Administration Medica l Center in 
C leveland, Ohio , report in this iss ue that coal tar shampoos induce 
enzy m e changes in hair follicles that are the initial step in carcin-
ogenesis. Hans M erk, Hasa n Mukhtar, Irene Kaufm ann , Mukul 
Das, and David Bickers find that polycyclic aro matic hyd ro-
ca rbons in coa l tar-containing shampoo are converted to several 
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metaboli c intermediates, including benzo[a]pyrene 7,8 diol, a 
major precurso r of the fin al ca rcinogeneic metabo lite of 
benzo l a ]pyrene. 
The group began this stud y, accordin g to Mukhtar, " beca use 
most human cancers are epithelial in origin and hair fo llicles are 
a source of pure epithelial tissue and are eas il y accessible." More-
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ova, he adds, there is a real need fo r well-defin ed system s to 
determine c;i rcinogeni city in hum ans. 
The ill ves ti gato rs looked fo r ev idence o f aryl hydrocarbon h y-
droxy lase ac ti v ity and in creased binding o f benzo l a lp yrene to 
DN A in th e hair fo llicles of ·12 vo lunteers, each of who m had 
used a coal tar-containing shampoo for the precedin g four days . 
T he enzy me and DNA binding arc indica to rs th at th e relativel y 
inert benzo lalpyrenc is ac tivated to a carcinogen . Follicles fro l11 
10 of the 12 vo lunteers showed these changes. Wh en the vo l-
T H E JOU RNA L OF IN VESTIGATIVE f) EI{M ATO LOC;y 
L1ntee rs were ad III in istered clo tri mazolc o r ketoconazo le, w h ich 
inhibit the metaboli sm o f benzo[a ]p yn:ne and prevent it fronl 
being ca rcinogeni c w hcn applied to rodent skin , the increased 
enzy mc acti vity and the D NA binding no longer occurred. 
The clinical impli cations o f this wo rk , accordin g to Mukh ta r , 
arc that consum ers m ay want to avo id coa l tar-containin g slull1_ 
poos w hose effi cacy, in any case, " is no r certain. " In 3dditi on , 
psori as is patients, who LIse coal tar preparations, should be ca re_ 
full y monito red fo r earl y signs o f ca nce r. 
Cyclosporine and Psoriasis 
Cyclos po rin e A , which specifi ca ll y inhibits helper T lympho-
cytes, has transfo rm ed th e fIeld of transplant m edicine. In 1984, 
cyclosporine A was reported to also be effecti ve against psori as is. 
In this issue, N aoko Kato of Hokkaido Uni ve rsit y Schoo l o f 
Medicine in Sappo ro, Japan , and Kenneth H alprin and J . Richard 
Taylo r of the University of Miami School o f M edi cine in Miami , 
Flo rid a, repo rt that cyclos porine A does not inhibit epidermal cell 
g rowth . This findin g suppo rts the concept that psorias is may be 
due to immunolog ical abnorm aliti es and specifi ca lly implica tes 
helper T cells as the immune cells m ost likely to be in vo lved in 
th e pathogenes is o f psoriasis. 
T he investi gato rs began their wo rk, sa ys H alprin , when they 
read that cyclospo rine contro ls pso riasis . This led them to give 
the dru g to four patients with severe psorias is w ho were un able 
to continue taking methotrexa te beca use th ey had developed cir-
rhos is. Cyclos po rin e effecti vely controlled their severe pso ri as is, 
bu t th ey ca nn o t stop taking it beca use, if they do, their les ions 
w ill recur. 
The effectiveness o f cyclosporine in trea tin g psori as is "fit with 
a belief that \ had ," says Halprin , " \ stron g ly beli eve that the 
activity o f helper T cells is essential fo r the maintenance of pso-
riati c lesions." 
The stud y published in this issue w as designed to rule out an 
alternati ve hypothesis-that cyclos porine ac ts by directl y inhib_ 
iting epiderm al cell growth. H alprin interprets his result as in-
di cating th at " helper T lymphocy tes are mo re important in pso -
riasis th an most people believe." A nUlll ber o f resea rchers focu s 
on po lym orph onuclea r lymphocytes and the produ cts o f arach_ 
idoni c acid metabolism th at attract PNRs to psoriati c lesions as 
possible ca uses of pso ri as is. 
Despite the fa ct th at cycl os po rin e contro ls psorias is, Halprin 
says he w ould no t g ive it to 111 0 re patients aga in beca use it is too 
toxi c-it lllay dam age th e kidney, it m ay produce hirsutism, and 
it is consistently immunosuppressive . Cyclospo rine lllust be given 
sys temi call y to be effecti ve. In addition, w hen H alprin and his 
colleagues tried using it to pically , they found it to be ineffective. 
